Huntington's Disease Market Research Report 2030 | Huntington's Disease Market 2030

Huntington’s disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain. It deteriorates a person’s physical and mental abilities usually during their prime working years and has no cure.

DelveInsight's "Huntington's Disease Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Huntington's Disease, historical and forecasted epidemiology as well as the Huntington's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Huntington's Disease Overview

Huntington’s disease is a hereditary neurodegenerative disorder caused by mutation in the HTT genes. The HTT mutation that causes Huntington disease involves a DNA segment known as a CAG trinucleotide repeat. This segment is made up of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear multiple times in a row.

An increase in the size of the CAG segment leads to the production of an abnormally long version of the huntingtin protein. The elongated protein is cut into smaller, toxic fragments that bind together and accumulate in neurons, disrupting the normal functions of these cells. The dysfunction and eventual death of neurons in certain areas of the brain underlie the signs and symptoms of Huntington disease.

Huntington’s Disease symptoms

1.    Personality changes

2.    Mood swings

3.    Depression

4.    Forgetfulness

5.    Impaired judgment

6.    Unsteady gait

7.    Involuntary movements (chorea)

8.    Slurred speech

9.    Swallowing difficulties

10. Significant weight loss

The DelveInsight Huntington's Disease market report gives a thorough understanding of the Huntington's Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. 

Request for sample pages of the report: https://www.delveinsight.com/sample-request/huntingtons-disease-market

Huntington's Disease Epidemiology  

Huntington’s disease (HD) is an inherited neurodegenerative disorder caused by a CAG triplet repeat expansion in the gene encoding huntingtin. HD is clinically characterized by a variable phenotypic expression of motor, cognitive and psychiatric symptoms, with typical age-at-onset in the thirties or forties and a slow disease progression

The Huntington's Disease epidemiology division provide insights about historical and current Huntington's Disease patient pool and forecasted trend for every seven major countries.

Key Findings

1.    According to a study by Swierzewski et al. titled “Huntington’s Disease Overview, Incidence and Prevalence of HD,” one in every 10,000 persons—nearly 30,000 in the United States—have Huntington's disease. Juvenile Huntington's occurs in approximately 16% of all cases.

2.    As per a study, the highest prevalence rates are reported for Western populations from Europe, where the minimum prevalence is >5 per 1,00,000. The minimum HD prevalence is estimated to be 0.1–0.5 per 1,00,000 in Japan.

As per the analysis, it is observed that the HD is more common in the European countries than the other countries in the 7MM.

Click here and get access to a sample report.

Huntington's Disease Key pharma players involved:

1.    Hoffmann-La Roche

2.    EIP Pharma

3.    Vaccinex

Huntington's Disease Emerging Therapies

1.    RG6042

2.    Neflamapimod

3.    Pepinemab

Huntington's Disease Market Outlook

According to the National Organization for Rare Diseases (NORD), Huntington's disease is a genetic, progressive, neurodegenerative disorder characterized by the gradual development of involuntary muscle movements affecting the hands, feet, face, and trunk, and progressive deterioration of cognitive processes and memory (dementia).

Currently, the market holds no treatment options for curing Huntington’s disease. However, there are effective treatments that support Huntington’s disease, including moving disorder, psychiatric disorders, and psychotherapy.

Medication management is likely to evolve over the course of the disease, depending on the overall treatment goals.

Expected launch of the upcoming therapies shall fuel the growth of the market during the forecast period, i.e., 2020–2030. The Huntington’s Disease market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase during the study period.

According to DelveInsight, Huntington's Disease market in 7MM is expected to change in the study period 2017-2030.

Visit our repository of reports @ https://www.delveinsight.com/report-store.php

 

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more